Phase 1 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been newly diagnosed with a specific type of brain lymphoma called primary CNS diffuse large B-cell lymphoma (DLBCL), confirmed by a sample taken from the brain, spinal fluid, or fluid from the eye
• People whose lymphoma is found only in the brain or central nervous system, with no signs of lymphoma elsewhere in the body (people with a past history of lymphoma limited to the eye that was treated only locally may still be considered eligible)
• People who have not yet received chemotherapy or whole-brain radiation treatment for this condition
• People aged 18 or older
• People who are well enough to carry out basic daily activities (a doctor will assess this using a standard scale)
• People whose blood counts, kidney function, liver function, and blood clotting results fall within acceptable ranges as assessed by a doctor
• People who test negative for HIV
• People with no history of organ transplantation and who are not currently taking medication to suppress their immune system
• Women who could become pregnant must have a negative blood pregnancy test taken within 72 hours before joining the trial
• Women who could become pregnant must agree to use a highly effective form of contraception throughout treatment and for 120 days after finishing the trial treatment
• Male participants must agree to use contraception from their first dose until 120 days after the last dose, either by using a condom together with their partner using a highly effective contraceptive method, or by being in a long-term pattern of abstinence from penile-vaginal intercourse

Who may not be able to join:

• People who are unable to have an MRI scan
• People whose lymphoma is limited only to the eye, with no involvement of the brain or spinal cord
• People currently taking part in another clinical trial involving an experimental treatment
• People who have had a severe allergic reaction to medicines that are chemically similar to the study drugs
• People who have previously been treated with certain immune checkpoint therapies (medicines that work on the PD-1, PD-L1, PD-L2, CTLA-4, OX-40, or CD137 pathways)
• People who have an active autoimmune disease that requires ongoing treatment with immune-suppressing medicines or steroids
• People who have received a live vaccine (such as measles, mumps, rubella, chickenpox, yellow fever, rabies, BCG, or nasal flu spray) within 30 days before starting the trial (injected seasonal flu vaccines and COVID-19 vaccines are generally permitted)
• People who have another cancer that is currently active or has required treatment within the past 3 years (some early-stage or successfully treated skin and in-situ cancers may not be excluded — confirm with trial site)
• People with a history of lung inflammation (pneumonitis) that needed steroid treatment, or who currently have pneumonitis
• People with poorly controlled diabetes, indicated by a blood sugar marker (HbA1c) above 8%
• People who are unable to swallow capsules, or who have a condition that significantly affects how the gut absorbs food or medicine
• People taking certain anti-seizure medications that affect how the body processes other drugs — these would need to be switched to a different type at least two weeks before starting the trial
• People with a known history of active Hepatitis B or Hepatitis C infection
• People with a known history of active tuberculosis (TB)
• People with a known immune deficiency condition, or who are taking steroid medication at a dose higher than the equivalent of 10 mg of prednisone per day on an ongoing basis
• People who have previously had an allogeneic stem cell transplant (a transplant using donor stem cells)
• People with large fluid build-ups in the chest or abdomen, or widespread body swelling
• People with known psychiatric conditions or substance use disorders that would make it difficult to follow the trial requirements
• People who are pregnant, breastfeeding, or planning to conceive a child during the study period or within 120 days after the last dose of trial treatment

Important: Always verify eligibility with the trial site directly before applying.